Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

HER2 protein, trastuzumab therapy

Trastuzumab exemplifies a growing number of monoclonal antibodies that have become available for antineoplastic therapy. These are directed against cell surface proteins that are strongly expressed by cancer cells. Trastuzumab binds to HER2, the recep-Luellmann, Color Atlas of Pharmacology All rights reserved. Usage subject to terms... [Pg.302]

TRASTUZUMAB Trastuzumab (herceptin) targets the HER2/neu (ErbB-2) member of the EGE family of protein tyrosine kinase receptors. Activation of HER2/neu enhances metastatic potential and inhibits apoptosis. HER2/neu is overexpressed in up to 30% of breast cancers and is associated with clinical resistance to cytotoxic and hormone therapy. Trastuzumab can initiate Fcy-receptor-mediated ADCC and directly induce apoptosis. [Pg.901]

See other pages where HER2 protein, trastuzumab therapy is mentioned: [Pg.1321]    [Pg.248]    [Pg.2358]    [Pg.29]    [Pg.92]    [Pg.1968]    [Pg.884]    [Pg.41]   


SEARCH



Protein therapy

Trastuzumab therapy

© 2024 chempedia.info